| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
A composite 18F-FDG PET/CT and HER2 tissue-based biomarker to predict response to neoadjuvant pertuzumab and trastuzumab in HER2-positive breast cancer (TBCRC026)
|
Hennessy, Maeve A.
|
|
|
81 |
C |
p.
|
artikel
|
| 2 |
Addressing key limitations in the study on DCIS response to neoadjuvant chemotherapy in TNBC
|
Venkataraman, Janhavi
|
|
|
81 |
C |
p.
|
artikel
|
| 3 |
Analysis of factors influencing chemotherapy-induced peripheral neuropathy in breast cancer patients using a random forest model
|
Xu, Huiqian
|
|
|
81 |
C |
p.
|
artikel
|
| 4 |
Awareness of genomic testing among patients with breast cancer in Europe
|
Cardone, Antonella
|
|
|
81 |
C |
p.
|
artikel
|
| 5 |
Beta blocker use and breast cancer survival by subtypes: A population-based cohort study
|
Scott, Oliver William
|
|
|
81 |
C |
p.
|
artikel
|
| 6 |
Biomarker alteration following chemotherapy-based systemic therapy in de novo metastatic breast cancer
|
Kong, Lingjun
|
|
|
81 |
C |
p.
|
artikel
|
| 7 |
CADONOT: Comparing axillary dissection or not in breast cancer surgery
|
Mattar, André
|
|
|
81 |
C |
p.
|
artikel
|
| 8 |
Climate change impacts and sustainability integration among breast international group members
|
O'Reilly, Seamus
|
|
|
81 |
C |
p.
|
artikel
|
| 9 |
Clinical characteristics and prognostic factors in patients with breast cancer and leptomeningeal metastases from a large registry of BMBC
|
Laakmann, Elena
|
|
|
81 |
C |
p.
|
artikel
|
| 10 |
Comparison of neoadjuvant and adjuvant chemotherapy for operable triple-negative breast cancer before the era of immune checkpoint inhibitors: A retrospective study from the Japanese National Clinical Database-Breast Cancer Registry
|
Taji, Tomoe
|
|
|
81 |
C |
p.
|
artikel
|
| 11 |
Comparison of oncological outcomes of premenopausal with ovarian function suppression versus postmenopausal women in ER+/HER2- breast cancer
|
Lee, Min Jung
|
|
|
81 |
C |
p.
|
artikel
|
| 12 |
Computational pathology for breast cancer: Where do we stand for prognostic applications?
|
Gessain, Grégoire
|
|
|
81 |
C |
p.
|
artikel
|
| 13 |
Corrigendum to “Beta blocker use and breast cancer survival by subtypes: A population-based cohort study” [The Breast 81 (2025) 104474]
|
Scott, Oliver William
|
|
|
81 |
C |
p.
|
artikel
|
| 14 |
Early prediction of cardiovascular events following treatments in female breast cancer patients: Application of real-world data and artificial intelligence
|
Nguyen, Quynh T.N.
|
|
|
81 |
C |
p.
|
artikel
|
| 15 |
Editorial Board
|
|
|
|
81 |
C |
p.
|
artikel
|
| 16 |
Efficacy of adjuvant capecitabine in triple-negative breast cancer with residual disease after neoadjuvant therapy: a real-world study
|
Ma, Youzhao
|
|
|
81 |
C |
p.
|
artikel
|
| 17 |
Fertility preservation in young breast cancer patients: A nationwide survey on knowledge, attitudes, and practices among breast surgical healthcare providers in China
|
Yuan, Xiaoling
|
|
|
81 |
C |
p.
|
artikel
|
| 18 |
Identifying germline pathogenic variants in breast cancer using tumor sequencing
|
Cruellas, Mara
|
|
|
81 |
C |
p.
|
artikel
|
| 19 |
Impact of routine FDG-PET/CT on locoregional treatment decisions in breast cancer patients receiving preoperative systemic therapy
|
Gunster, Jetske L.B.
|
|
|
81 |
C |
p.
|
artikel
|
| 20 |
Influence of surgical timing post-neoadjuvant chemotherapy on survival outcomes in breast cancer patients: A comprehensive systematic review and meta-analysis
|
Wang, Dandan
|
|
|
81 |
C |
p.
|
artikel
|
| 21 |
Innovations in the localization techniques for non-palpable breast lesions: Make invisible visible
|
Lin, Quankun
|
|
|
81 |
C |
p.
|
artikel
|
| 22 |
Integration of translational research in phase III trials: A systematic review of breast cancer studies in a 5-year period
|
Giannone, G.
|
|
|
81 |
C |
p.
|
artikel
|
| 23 |
Is switching to T-DM1 still justified in HER2-negative residual breast cancer after neoadjuvant systemic therapy?
|
Tjalma, Wiebren
|
|
|
81 |
C |
p.
|
artikel
|
| 24 |
Long-term outcomes of three distinct once-daily schedules for accelerated partial breast irradiation
|
Vinante, Lorenzo
|
|
|
81 |
C |
p.
|
artikel
|
| 25 |
Mapping breast cancer therapy with circulating tumor cells: The expert perspective
|
Gerratana, Lorenzo
|
|
|
81 |
C |
p.
|
artikel
|
| 26 |
Paclitaxel-related type I Kounis Syndrome in a very young patient with HER2-positive breast cancer and the role of genomics to disentangle a complex therapeutic scenario: a case report and narrative review
|
Muñoz, Javier
|
|
|
81 |
C |
p.
|
artikel
|
| 27 |
Patient perception on risk of recurrence and decision-making in the management of HER2-positive early breast cancer: Insights from the ASKHER2 European survey
|
Lambertini, Matteo
|
|
|
81 |
C |
p.
|
artikel
|
| 28 |
Prognostic factors and treatment insights for metastatic malignant phyllode tumors
|
Han, Mengjia
|
|
|
81 |
C |
p.
|
artikel
|
| 29 |
Reaction to ‘addressing key limitations in the study on DCIS response to neoadjuvant chemotherapy in TNBC’
|
Claassens, Eva L.
|
|
|
81 |
C |
p.
|
artikel
|
| 30 |
Real-world palbociclib dose modifications and clinical outcomes in patients with HR+/HER2− metastatic breast cancer: A Flatiron Health database analysis
|
Layman, Rachel M.
|
|
|
81 |
C |
p.
|
artikel
|
| 31 |
Real-world risk of recurrence and treatment outcomes with adjuvant endocrine therapy in patients with stage II-III HR+/HER2- early breast cancer
|
O'Shaughnessy, Joyce
|
|
|
81 |
C |
p.
|
artikel
|
| 32 |
Real-world utilization of aromatase inhibitors, tamoxifen, and ovarian function suppression in premenopausal patients with early hormone receptor-positive, HER2-negative breast cancer with increased recurrence risk
|
Müller, Volkmar
|
|
|
81 |
C |
p.
|
artikel
|
| 33 |
Reevaluating prognostic differences in HR+/HER2− Breast Cancer: The unaccounted impact of CDK4/6 inhibitors
|
Önder, Arif Hakan
|
|
|
81 |
C |
p.
|
artikel
|
| 34 |
Self-reported cognitive function in older breast cancer survivors after chemotherapy treatment
|
Kim, Rachel
|
|
|
81 |
C |
p.
|
artikel
|
| 35 |
Socioeconomic disparities and osteoarthritis impact hormone therapy adherence in breast cancer
|
Jang, B.S.
|
|
|
81 |
C |
p.
|
artikel
|
| 36 |
Switching to T-DM1 remains justified in patients with HER2-negative residual invasive breast cancer after neoadjuvant therapy
|
Geyer Jr., Charles E.
|
|
|
81 |
C |
p.
|
artikel
|
| 37 |
Systematic literature review and trial-level meta-analysis of aromatase inhibitors vs tamoxifen in patients with HR+/HER2− early breast cancer
|
Janni, Wolfgang
|
|
|
81 |
C |
p.
|
artikel
|
| 38 |
The ideal strategies of antibody‒drug conjugate sequential treatment in HER2-expressing metastatic breast cancer: A multi-center real-world study
|
Peng, Xuenan
|
|
|
81 |
C |
p.
|
artikel
|
| 39 |
The relationship between decision regret, quality of life, and mindfulness in early-stage breast cancer survivors
|
Kao, Yu-Ling
|
|
|
81 |
C |
p.
|
artikel
|
| 40 |
Towards precision therapy in HER2-positive early-stage breast cancer
|
Di Cosimo, Serena
|
|
|
81 |
C |
p.
|
artikel
|
| 41 |
Trajectories and predictors of financial toxicity in breast cancer patients: A multicenter longitudinal study in China
|
Kuang, Yi
|
|
|
81 |
C |
p.
|
artikel
|
Tijdschrift beschrijving